Mani Foroohar
Stock Analyst at Leerink Partners
(2.40)
# 2,441
Out of 5,182 analysts
172
Total ratings
50.52%
Success rate
-2.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Maintains: Outperform | $8 → $9 | $4.44 | +102.70% | 2 | Apr 2, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $13.04 | +122.39% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $72.23 | +43.98% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $92.48 | +27.60% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $8.62 | +132.02% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $74.52 | +15.41% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $308.51 | +13.77% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $48.70 | -63.04% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $5.63 | +255.56% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.49 | +100.57% | 13 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $45 → $10 | $20.98 | -52.34% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $3.48 | +72.41% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $9.45 | +185.71% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $27.05 | +166.17% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $6.94 | +217.00% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.61 | +3.09% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $11.74 | +147.02% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.20 | +330.56% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.70 | +900.00% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $73.60 | -45.65% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.89 | +142.21% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $29.17 | +164.02% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.34 | +12.36% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $50.99 | +49.05% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.13 | +1,496.24% | 4 | May 12, 2022 |
Camp4 Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $8 → $9
Current: $4.44
Upside: +102.70%
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $13.04
Upside: +122.39%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $72.23
Upside: +43.98%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $92.48
Upside: +27.60%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $8.62
Upside: +132.02%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $74.52
Upside: +15.41%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $308.51
Upside: +13.77%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $48.70
Upside: -63.04%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $5.63
Upside: +255.56%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.49
Upside: +100.57%
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $20.98
Upside: -52.34%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.48
Upside: +72.41%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $9.45
Upside: +185.71%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $27.05
Upside: +166.17%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.94
Upside: +217.00%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.61
Upside: +3.09%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $11.74
Upside: +147.02%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.20
Upside: +330.56%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.70
Upside: +900.00%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $73.60
Upside: -45.65%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.89
Upside: +142.21%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $29.17
Upside: +164.02%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.34
Upside: +12.36%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $50.99
Upside: +49.05%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.13
Upside: +1,496.24%